CA Patent

CA2462657A1 — Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity

Assigned to Novartis AG · Expires 2003-05-08 · 23y expired

What this patent protects

The present invention relates to the use of staurosporines derivatives for t he preparation of a drug for the treatment of diseases involving deregulated FL T3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodyspl…

USPTO Abstract

The present invention relates to the use of staurosporines derivatives for t he preparation of a drug for the treatment of diseases involving deregulated FL T3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.

Drugs covered by this patent

Patent Metadata

Patent number
CA2462657A1
Jurisdiction
CA
Classification
—
Expires
2003-05-08
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.